Previous 10 | Next 10 |
Chardan Capital Markets has initiated Senti Biosciences ( NASDAQ: SNTI ) with a buy highlighting the potential of the company's gene circuit synthetic biology platform and engineered cell therapy pipeline. The firm says the platform and pipeline can "address several l...
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks this morning is an acquisition deal, an update from ...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO...
Chardan Announces Launch of ChEF (Chardan Equity Facility) PR Newswire NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution used t...
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that on August 18, 2022,...
Senti Biosciences press release ( NASDAQ: SNTI ): Q2 GAAP EPS of -$0.86. Revenue of $1.36M (+72.2% Y/Y). As of June 30, 2022, Senti Bio held cash and cash equivalents of $139.8M, which the company believes is sufficient to fund operations into 2024. For further d...
- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - - Cash position of $139.8 million as of June 30, 2022 expected to fund curren...
Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...
Hydrofarm Holdings Group HYFM -27% on slashed guidance amid hydroponics recession . Meihua International Medical Technologies ( MHUA ) -13% . MDJM ( MDJH ) -21% . Match Group MTCH -21% on Q2 earnings release . Horizon Therapeutics Public...
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
Senti Biosciences Inc. Website:
2024-07-18 09:02:04 ET SNTI (SNTI) announced stock split at a ratio of 1-for-10 on 2024-07-18 ... Full story available on KlickAnalytics.com
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors h...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...